Group B Streptococcus Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A Follow up Study of Group B Streptococcus Vaccine (GBS-NN/NN2 Vaccine) in Healthy Volunteers
Conditions: Group B Streptococcus Infection Interventions: Biological: GBS-NN/NN2 Sponsors: Minervax ApS; Simbec-Orion Group Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials

Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate
Results from an ongoing Phase 2 study in pregnant individuals showed the investigational vaccine, GBS6, was generally well-tolerated and generated robust maternal antibody responses that were efficiently transferred to infants The safety profile... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 19, 2023 Category: Pharmaceuticals Source Type: clinical trials

Invasive Group B Streptococcus Disease Burden and Its Antimicrobial Resistance in Malaysia Among Non-pregnant Adults.
Conditions: Invasive Infection; Diabetic Foot; Immunocompromised Patients; Group B Streptococcal Infections Intervention: Other: No Intervention in This study Sponsor: Universiti Putra Malaysia Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 13, 2023 Category: Research Source Type: clinical trials

Invasive Group B Streptococcus Disease Burden and Its Antimicrobial Resistance in Malaysia Among Non-pregnant Adults: a Prospective Observational Protocol Study
Condition: Invasive Group B Streptococcus Disease Among Non-pregnant Adult Intervention: Other: No Intervention in This study Sponsor: Universiti Putra Malaysia Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 13, 2023 Category: Research Source Type: clinical trials

FDA Grants Breakthrough Therapy Designation to Pfizer ’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women
NEW YORK--(BUSINESS WIRE) September 07, 2022 -- Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designation from the U.S. Food and Drug... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 7, 2022 Category: Pharmaceuticals Source Type: clinical trials

Group B Streptococcus Colonization in Mother-newborn Dyads and Association With Serotype-specific Capsular Antibodies in Karachi, Pakistan.
Condition: Group B Streptococcus (GBS) Colonization Intervention: Sponsors: Aga Khan University; Centers for Disease Control and Prevention; Emory University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 21, 2022 Category: Research Source Type: clinical trials